{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:10:57Z","timestamp":1791587457703,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The optimal blood pressure (BP) management level for patients with heart failure (HF) with preserved ejection fraction (HFpEF) remains unclear. In conjunction with the upcoming the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2025 (JSH2025), we conducted a systematic review and meta-analysis to evaluate whether managing systolic BP (SBP)\u2009&lt;\u2009130\u2009mmHg improves outcomes in HFpEF patients. We searched PubMed, Cochrane and Ichishi for randomized controlled trials (RCTs) published since 2012 that targeted HFpEF patients; used strict BP control, antihypertensive medications, or intensive HF management as interventions; demonstrated significant BP reduction with achieved SBP\u2009&lt;\u2009130\u2009mmHg in intervention groups; and had follow-up periods \u22656 months. Six studies were included, evaluating mineralocorticoid receptor antagonists (<jats:italic>n<\/jats:italic>\u2009=\u20092), angiotensin receptor-neprilysin inhibitors (<jats:italic>n<\/jats:italic>\u2009=\u20092), intensive BP control (<jats:italic>n<\/jats:italic>\u2009=\u20091), and intensive HF management (<jats:italic>n<\/jats:italic>\u2009=\u20091). Meta-analysis showed that achieving SBP\u2009&lt;\u2009130\u2009mmHg significantly reduced HF hospitalizations (relative risk [RR] [95% confidence interval (CI)] 0.80 [0.69\u20130.93], <jats:italic>p<\/jats:italic>\u2009=\u20090.005) and demonstrated a trend toward reduced all-cause mortality (RR [95% CI] 0.74 [0.53\u20131.04], <jats:italic>p<\/jats:italic>\u2009=\u20090.083). While hypotension increased (RR [95% CI] 1.35 [1.03\u20131.79], <jats:italic>p<\/jats:italic>\u2009=\u20090.03), there was no significant increase in renal dysfunction or serious adverse events. Despite limitations from indirectness (no RCTs specifically targeted SBP\u2009&lt;\u2009130\u2009mmHg as primary intervention), our findings suggest that achieving SBP\u2009&lt;\u2009130\u2009mmHg in HFpEF patients may improve clinical outcomes. We recommend managing HFpEF patients to achieve SBP\u2009&lt;\u2009130\u2009mmHg, while carefully monitoring for hypotension.<\/jats:p>","DOI":"10.1038\/s41440-025-02240-w","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T03:20:34Z","timestamp":1747970434000},"page":"2138-2151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Systolic blood pressure lower than 130\u2009mmHg in heart failure with preserved ejection fraction: a systematic review and meta-analysis of clinical outcomes"],"prefix":"10.1038","volume":"48","author":[{"given":"Chisa","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagisa","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatomi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"2240_CR1","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789-858."},{"key":"2240_CR2","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.03","volume":"9","author":"CJ Kapelios","year":"2023","unstructured":"Kapelios CJ, Shahim B, Lund LH, Savarese G. Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction. Card Fail Rev. 2023;9:e14.","journal-title":"Card Fail Rev"},{"key":"2240_CR3","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392.","journal-title":"N Engl J Med"},{"key":"2240_CR4","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381:1609\u201320.","journal-title":"N Engl J Med"},{"key":"2240_CR5","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456\u201367.","journal-title":"N Engl J Med"},{"key":"2240_CR6","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338\u201345.","journal-title":"Eur Heart J"},{"key":"2240_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777\u201381.","journal-title":"Lancet"},{"key":"2240_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41440-019-0216-8","volume":"42","author":"H Kawano","year":"2019","unstructured":"Kawano H, Fujiwara A, Kai H, Kumagai E, Okamoto R, Shibata R, et al. Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. Hypertens Res. 2019;42:504\u201313.","journal-title":"Hypertens Res"},{"key":"2240_CR9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2240_CR10","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"2240_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","volume":"14","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, B\u00f6hm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803\u201369.","journal-title":"Eur J Heart Fail"},{"key":"2240_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008322","volume":"14","author":"B Upadhya","year":"2021","unstructured":"Upadhya B, Willard JJ, Lovato LC, Rocco MV, Lewis CE, Oparil S, et al. Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT. Circ Heart Fail. 2021;14:e008322.","journal-title":"Circ Heart Fail"},{"key":"2240_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018827","volume":"9","author":"T Tsujimoto","year":"2020","unstructured":"Tsujimoto T, Kajio H. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension. J Am Heart Assoc. 2020;9:e018827.","journal-title":"J Am Heart Assoc"},{"key":"2240_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.","journal-title":"Bmj"},{"key":"2240_CR15","unstructured":"ed. MMDC. Minds Manual for Guideline Development 2020 ver. 3.0. Japan Council for Quality Health Care: Tokyo, Japan, 2021."},{"key":"2240_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","volume":"141","author":"JJV McMurray","year":"2020","unstructured":"McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, et al. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation. 2020;141:338\u201351.","journal-title":"Circulation"},{"key":"2240_CR17","unstructured":"Julian Higgins JT, Jacqueline Chandler, Miranda Cumpston, Tianjing Li, Matthew Page4 Vivian Welch. Cochrane Handbook for Systematic Reviews of Interventions Version 6.5, 2024. https:\/\/training.cochrane.org\/handbook\/current\/chapter-10. 2024."},{"key":"2240_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","volume":"119","author":"N Santesso","year":"2020","unstructured":"Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126\u201335.","journal-title":"J Clin Epidemiol"},{"key":"2240_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"2240_CR20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. Jama. 2013;309:781\u201391.","journal-title":"Jama"},{"key":"2240_CR21","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387\u201395.","journal-title":"Lancet"},{"key":"2240_CR22","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.jacc.2023.03.426","volume":"81","author":"M Pagnesi","year":"2023","unstructured":"Pagnesi M, Metra M, Cohen-Solal A, Edwards C, Adamo M, Tomasoni D, et al. Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2023;81:2131\u201344.","journal-title":"J Am Coll Cardiol"},{"key":"2240_CR23","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl J Med. 2015;373:2103\u201316.","journal-title":"N. Engl J Med"},{"key":"2240_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/HCO.0000000000000852","volume":"36","author":"PL Myhre","year":"2021","unstructured":"Myhre PL, Selvaraj S, Solomon SD. Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal? Curr Opin Cardiol. 2021;36:413\u20139.","journal-title":"Curr Opin Cardiol"},{"key":"2240_CR25","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"key":"2240_CR26","doi-asserted-by":"crossref","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024:66.","DOI":"10.1093\/ehjcvp\/pvae084"},{"key":"2240_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042220-022745","volume":"73","author":"K Omote","year":"2022","unstructured":"Omote K, Verbrugge FH, Borlaug BA. Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. Annu Rev Med. 2022;73:321\u201337.","journal-title":"Annu Rev Med"},{"key":"2240_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","volume":"15","author":"K Yamamoto","year":"2013","unstructured":"Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013;15:110\u20138.","journal-title":"Eur J Heart Fail"},{"key":"2240_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1023\/A:1025387702212","volume":"17","author":"M Zi","year":"2003","unstructured":"Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther. 2003;17:133\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"key":"2240_CR30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"2240_CR31","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/ejhf.2421","volume":"24","author":"FR Mc Causland","year":"2022","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, Packer M, Senni M, Gori M, et al. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022;24:1591\u20138.","journal-title":"Eur J Heart Fail"},{"key":"2240_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.604017","volume":"12","author":"Y Xu","year":"2021","unstructured":"Xu Y, Chen Y, Zhao JW, Li C, Wang AY. Effect of Angiotensin-Neprilysin Versus Renin-Angiotensin System Inhibition on Renal Outcomes: A Systematic Review and Meta-Analysis. Front Pharm. 2021;12:604017.","journal-title":"Front Pharm"},{"key":"2240_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11897-020-00463-1","volume":"17","author":"G Tersalvi","year":"2020","unstructured":"Tersalvi G, Dauw J, Martens P, Mullens W. Impact of Sacubitril-Valsartan on Markers of Glomerular Function. Curr Heart Fail Rep. 2020;17:145\u201352.","journal-title":"Curr Heart Fail Rep."},{"key":"2240_CR34","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","volume":"44","author":"K Yamamoto","year":"2021","unstructured":"Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment. Hypertens Res. 2021;44:1239\u201350.","journal-title":"Hypertens Res"},{"key":"2240_CR35","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391:1475\u201385.","DOI":"10.1056\/NEJMe2410904"},{"key":"2240_CR36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"2240_CR37","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559\u201373.","journal-title":"Stat Med"},{"key":"2240_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34\u201342.","journal-title":"Circulation"},{"key":"2240_CR39","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1097\/HJH.0000000000003177","volume":"40","author":"R Huang","year":"2022","unstructured":"Huang R, Wu R, Lin Y, Zhong X, Ye X, Zhuang X, et al. Time-averaged cumulative blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: analysis from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. J Hypertens. 2022;40:1918\u201326.","journal-title":"J Hypertens"},{"key":"2240_CR40","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","volume":"75","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj S, Claggett BL, B\u00f6hm M, Anker SD, Vaduganathan M, Zannad F, et al. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril\/Valsartan. J Am Coll Cardiol. 2020;75:1644\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"2240_CR41","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N. Engl J Med. 2021;385:1451\u201361.","journal-title":"N. Engl J Med"},{"key":"2240_CR42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N. Engl J Med. 2023;389:1069\u201384.","journal-title":"N. Engl J Med"},{"key":"2240_CR43","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N. Engl J Med. 2023;389:2221\u201332.","journal-title":"N. Engl J Med"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02240-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02240-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02240-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:31:05Z","timestamp":1757172665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02240-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2240"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02240-w","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}